BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editi… Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
- Verve Therapeutics Inc (VERV) is around the top of the Healthcare sector according to InvestorsObserver.
- The investor’s estimated purchase price is $156 Million, resulting in a loss of 52%.
- CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course…
- The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
Additionally, Verve Therapeutics Inc scored a 69 in the Healthcare sector, ranking it higher than 69% of stocks in that sector. Fears of an impending recession have been a drag on the stock market for quite a while now. As the Fed continues to stay hawkish, a global recession seems imminent. The biotech stock rose nearly $7 a share from Monday through Thursday. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
VERV Stock – Frequently Asked Questions
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under
management must also disclose their put and call option holdings. Since put options generally indicate
negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall
institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots
the historical put/call ratio for this instrument. Verve Therapeutics Inc. is set to go public Thursday, after the Massachusetts-based biotechnology company’s upsized initial public offering priced overnight above the expected range to value the company at about $832.6 mi…
Verve Therapeutics Inc Up 7.04% To $19.47 After Earnings Beat – InvestorsObserver
Verve Therapeutics Inc Up 7.04% To $19.47 After Earnings Beat.
Posted: Thu, 02 Mar 2023 08:00:00 GMT [source]
Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Cathie Wood acquired 4.48 Million Verve Therapeutics shares worth $74.5 Million. The investor’s estimated purchase price is $156 Million, resulting in a loss of 52%.
And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Verve Therapeutics Inc (VERV) is around the top of the Healthcare sector according to InvestorsObserver. VERV received an overall rating of 34, which means that it scores higher than 34% of stocks.
We’d like to share more about how we work and what drives our day-to-day business. Compare
VERV’s historical performance
against its industry peers and the overall market. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
‘Squeezable’ AMC, GameStop stocks break out to multi-month highs
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly. The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.
8 analysts have issued twelve-month price targets for Verve Therapeutics’ stock. On average, they expect the company’s share price to reach $38.63 in the next twelve months. This suggests a possible upside of 127.5% from the stock’s current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.
Verve’s Stock Price Could Continue To Rise Through Clinical Progress – Despite Worries About “DeeperPocketed” Competition – Yahoo Finance
Verve’s Stock Price Could Continue To Rise Through Clinical Progress – Despite Worries About “DeeperPocketed” Competition.
Posted: Thu, 06 Oct 2022 07:00:00 GMT [source]
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. 13D/G filings can be filed by
groups of investors (with one leading), whereas 13F filings cannot.
Passively-managed funds do not typically buy options, so the put/call
ratio indicator more closely tracks the sentiment of actively-managed funds. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform. Verve Therapeutics’ stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (11.03%), ARK Investment Management LLC (7.25%), BlackRock Inc. (5.73%), State Street Corp (5.41%), Federated Hermes Inc. (3.88%) and Sumitomo Mitsui Trust Holdings Inc. (2.58%).
We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. CAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course … CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course…
Verve is a Silicon Valley software company focused exclusively on developing embedded technology for process and workflow management. Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million. Verve Therapeutics (VERV) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.78. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Terms of Service apply. Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present
them separately. The Fund Sentiment Score (fka Ownership Accumulation Score) finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-factor quantitative model that identifies companies
with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners,
the changes in portfolio allocations in those owners
and other metrics. The number ranges from 0 to 100,
with higher numbers indicating a higher level of accumulation to its peers,
and 50 being the average.
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle. CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already https://business-oppurtunities.com/some-straight-talk-about-career-training/ been used in a variety of applications, including gene editing, gene therapy, and disease… MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing med… BOSTON, March 27, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing me… BOSTON, May 09, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medi…
8 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” VERV shares.
Provides a general description of the business conducted by this company. The two clinical-stage gene-editing companies have good long-term prospects. Get this delivered to your inbox, and more info about our products and services. EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, Burt A. Adelman, and Barry Ticho in 2018 and is headquartered in Boston, MA. Verve Therapeutics Inc. shares soared 68% in their trading debut Thursday, after the Massachusetts-based biotechnology company’s upsized initial public offering priced above the expected range to value the company at abou… EquityZen helps investors to access private companies and their employees to sell shares.
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they’re going out of style. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.